Age-appropriate visual testing is recommended throughout the first decade of life to identify children requiring increased surveillance. 3 MRI does not predict clinical behaviour or preclude the later development of an OPG; moreover, incidentally identified NF1-associated OPGs rarely progress or require treatment. 4 In the absence of refractive error, reduced visual acuity or proptosis in a child with NF1 is highly predictive of an OPG, while cataracts and retinal disease are rarely detected in this population. The significant causes of non-correctible visual loss in NF1 children are OPG, glaucoma secondary to a plexiform neurofibroma involving the eyelid, or proptosis and optic nerve damage due to a retro-orbital plexiform neurofibroma. While the latter two may be visible, detailed ophthalmological examination including fundoscopy is necessary to detect a symptomatic OPG.
In current practice, the goal of annual age-appropriate visual assessments in children with NF1 is to identify abnormalities in visual function attributable to an OPG. These assessments should continue until at least 7 years of age, when the risk of visual impairments from OPG is significantly reduced. 4, 5 The finding of non-refractive decreased visual acuity warrants neuroimaging for identification and localisation of OPG, followed by serial visual testing and neuroimaging. Visual progression, defined as a two-line decrement in visual acuity, is an indication for chemotherapy.
Recently, the National Commissioning Group funded a 'Complex NF1' service in London and Manchester. A cardinal aim is to work with local ophthalmologists and optometrists to perform annual visual screening for OPG in NF1 children under 8 years. This prospective assessment will facilitate a nationally cohesive screening programme for OPG in a high-risk group of children.
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